2025
Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene
Johnson J, Siblini H, Al‐Hendy A, Segars J, González F, Taylor H, Singh B, Carson S, Christman G, Huang H, Dangi B, Zhang H. Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene. Clinical And Translational Science 2025, 18: e70189. PMID: 40077973, PMCID: PMC11903501, DOI: 10.1111/cts.70189.Peer-Reviewed Original ResearchConceptsEpigallocatechin-3-gallateFolate levelsUterine fibroidsClinical trialsGreen tea extractAssociated with folate deficiencyPresence of MTHFRWomen of Childbearing AgeSerum folate levelsReduced folate levelsActive clinical trialsReproductive-age womenEffect of epigallocatechin gallateDHFR genotypeDHFR polymorphismTea extractDaily doseClomiphene citrateUnexplained infertilityFolate deficiencyChildbearing ageClinical studiesTreated womenFibroidsLetrozole
2023
Standardising outcome reporting for clinical trials of interventions for heavy menstrual bleeding: Development of a core outcome set
Cooper N, Rivas C, Munro M, Critchley H, Clark T, Matteson K, Papadantonaki R, Yorke S, Tan A, Rodriguez M, Bongers M, Al‐Hendy A, Bahamondes L, Connolly A, Farquhar C, Valbrun T, Hickey M, Taylor H, Toub D, Vannuccini S, Iliodromiti S, Khan K. Standardising outcome reporting for clinical trials of interventions for heavy menstrual bleeding: Development of a core outcome set. BJOG An International Journal Of Obstetrics & Gynaecology 2023, 130: 1337-1345. PMID: 37055716, DOI: 10.1111/1471-0528.17473.Peer-Reviewed Original ResearchConceptsHeavy menstrual bleedingCore outcomeFinal COSMenstrual bleedingClinical trialsConsensus meetingSystematic reviewSeverity of dysmenorrhoeaNumber of patientsPotential core outcomesInternational Consensus MeetingQuality of lifeDelphi surveyTwo-round Delphi surveyAdverse eventsBlood lossHemoglobin levelsFuture trialsGynecology DepartmentCOMET InitiativePatient satisfactionClinical guidelinesResource settingsOnline international surveyFurther treatment
2021
Willingness of Women with Endometriosis Planning to Undergo IVF to Participate in a Randomized Clinical Trial and the Effects of the COVID-19 Pandemic on Potential Participation
Pretzel S, Kuhn K, Pal L, Polotsky A, Taylor HS, Zhang H, Robins J, Young SL, Santoro N. Willingness of Women with Endometriosis Planning to Undergo IVF to Participate in a Randomized Clinical Trial and the Effects of the COVID-19 Pandemic on Potential Participation. Reproductive Sciences 2021, 29: 620-626. PMID: 34363198, PMCID: PMC8345905, DOI: 10.1007/s43032-021-00705-0.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultChoice BehaviorCOVID-19Double-Blind MethodElectronic Health RecordsEndometriosisFemaleFertility Agents, FemaleFertilization in VitroGonadotropin-Releasing HormoneHealth Knowledge, Attitudes, PracticeHormone AntagonistsHumansInfertility, FemaleLive BirthPatient SelectionPregnancyPregnancy RateResearch SubjectsTreatment OutcomeUnited StatesYoung AdultConceptsGnRH antagonistClinical trialsEndometriosis diagnosisSuperior live birth ratesCOVID-19Relevant ICD-10 codesOral GnRH antagonistLive birth rateAge-eligible womenICD-10 codesElectronic medical recordsSurvey of womenIVF cyclesEligible womenWillingness of womenInfertility diagnosisMedical recordsFertility treatmentIVFWomenDiagnosisTrialsBirth rateTreatmentCOVID-19 pandemic
2020
Factors associated with study protocol adherence and bio banking participation in reproductive medicine clinical trials and their relationship to live birth
Engmann L, Sun F, Legro RS, Diamond MP, Zhang H, Santoro N, Bartlebaugh C, Dodson W, Estes S, Ober J, Brzyski R, Easton C, Hernandez A, Leija M, Pierce D, Robinson R, Awonuga A, Cedo L, Cline A, Collins K, Krawetz S, Puscheck E, Singh M, Yoscovits M, Barnhart K, Coutifaris C, Lecks K, Martino L, Marunich R, Snyder P, Alvero R, Comfort A, Crow M, Schlaff W, Casson P, Hohmann A, Mallette S, Christman G, Ohl D, Ringbloom M, Tang J, Bates G, Mason S, DiMaria N, Usadi R, Lucidi R, Rhea M, Baker V, Turner K, Trussell J, DelBasso D, Huang H, Li Y, Makuch R, Patrizio P, Sakai L, Scahill L, Taylor H, Thomas T, Tsang S, Yan Q, Zhang M, Haisenleder D, Lamar C, DePaolo L, Herring A, Redmond J, Thomas M, Turek P, Wactawski-Wende J, Rebar R, Cato P, Dukic V, Lewis V, Schlegel P, Witter F. Factors associated with study protocol adherence and bio banking participation in reproductive medicine clinical trials and their relationship to live birth. Human Reproduction 2020, 35: 2819-2831. PMID: 33190149, PMCID: PMC8453415, DOI: 10.1093/humrep/deaa232.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeClinical trial protocolMedicine clinical trialsU10 HD055942U10 HD38998Baseline characteristicsTrial protocolClinical trialsLive birthsPolycystic Ovary Syndrome IIU10 HD38992U10 HD39005U10 HD27049STUDY FUNDING/COMPETINGMultiple Intrauterine GestationsStudy protocol adherenceUS multicenter trialRegular ovulatory cyclesClinical trial findingsPolycystic ovarian morphologyPARTICIPANTS/MATERIALSROLE OF CHANCELower household incomeAfrican AmericansAspects of adherenceResponsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis
Pokrzywinski RM, Soliman AM, Snabes MC, Chen J, Taylor HS, Coyne KS. Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis. Fertility And Sterility 2020, 115: 423-430. PMID: 33066973, DOI: 10.1016/j.fertnstert.2020.07.013.Peer-Reviewed Original ResearchConceptsSevere endometriosis-associated painEndometriosis-associated painNumerical rating scaleNonmenstrual pelvic painPelvic painWorst painMonth 3Rating ScalePain numerical rating scaleMeaningful changePremenopausal womenSevere endometriosisGlobal ImpressionClinical trialsMAIN OUTCOMEPainDysmenorrheaPhase IIIWomenElagolixResponsivenessTrialsPlaceboEndometriosisPatientsEFFICACY AND SAFETY OF LINZAGOLIX (LGX) FOR THE TREATMENT OF HEAVY MENSTRUAL BLEEDING (HMB) DUE TO UTERINE FIBROIDS (UF): RESULTS FROM TWO PHASE 3 RANDOMIZED CLINICAL TRIALS
Stewart E, Taylor H, Taylor R, Donnez J, Bestel E, Gotteland J, Humberstone A, Garner E. EFFICACY AND SAFETY OF LINZAGOLIX (LGX) FOR THE TREATMENT OF HEAVY MENSTRUAL BLEEDING (HMB) DUE TO UTERINE FIBROIDS (UF): RESULTS FROM TWO PHASE 3 RANDOMIZED CLINICAL TRIALS. Fertility And Sterility 2020, 114: e522. DOI: 10.1016/j.fertnstert.2020.09.016.Peer-Reviewed Original ResearchTreatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial
Donnez J, Taylor HS, Taylor RN, Akin MD, Tatarchuk TF, Wilk K, Gotteland JP, Lecomte V, Bestel E. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial. Fertility And Sterility 2020, 114: 44-55. PMID: 32505383, DOI: 10.1016/j.fertnstert.2020.02.114.Peer-Reviewed Original ResearchConceptsEndometriosis-associated painBone mineral densityNon-menstrual pelvic painPelvic painDose-dependent fashionSerum estradiolOral gonadotropin-releasing hormone antagonistSevere endometriosis-associated painGonadotropin-releasing hormone antagonistOverall pelvic painRates of amenorrheaDose-ranging trialRandomized clinical trialsNumber of respondersPrimary endpointBMD lossTotal hipFemoral neckHormone antagonistClinical centersParallel groupClinical trialsMineral densityLife measuresMAIN OUTCOME
2019
Responsiveness Evaluation and Recommendation for Responder Thresholds for Endometriosis Health Profile-30: Analysis of Two Phase III Clinical Trials
Pokrzywinski R, Soliman A, Chen J, Snabes M, Taylor H, Coyne K. Responsiveness Evaluation and Recommendation for Responder Thresholds for Endometriosis Health Profile-30: Analysis of Two Phase III Clinical Trials. Journal Of Women's Health 2019, 29: 253-261. PMID: 31855102, DOI: 10.1089/jwh.2019.7788.Peer-Reviewed Original ResearchConceptsEndometriosis Health Profile-30Nonmenstrual pelvic painClinical trialsResponder thresholdSevere endometriosis-associated painPhase III clinical trialsEndometriosis-associated painEndometriosis-related painPatient Global ImpressionGoal of treatmentPatient-reported impactPelvic painMonth 3Month 6EHP-30Global ImpressionTreatment efficacyDay 1Large effect sizesHealth statusPainResponsiveness evaluationDaily diariesPhase IIIDistribution-based analysisBaseline endometriosis-associated pain burden: Data from 1600+ women enrolled in elagolix clinical trials
Leyland N, Estes S, Eichner S, Soliman A, Mai Y, Snabes M, Taylor H, Surrey E. Baseline endometriosis-associated pain burden: Data from 1600+ women enrolled in elagolix clinical trials. Journal Of Endometriosis And Pelvic Pain Disorders 2019, 11: 117-125. DOI: 10.1177/2284026519864232.Peer-Reviewed Original ResearchEndometriosis-associated painNonmenstrual pelvic painPelvic painClinical trialsMean Numeric Rating Scale scoreSevere endometriosis-associated painPlacebo-controlled clinical trialGonadotropin-releasing hormone antagonistNumeric rating scale scoreRescue medication usePhase 3 studyNumeric rating scaleRating Scale scoresScreening phaseBaseline painEndometriosis medicationsPain burdenEndometriosis painMedication useHormone antagonistScreening periodPainScale scoreDaily burdenStudy participantsImpact of Elagolix on Quality of Life Among Endometriosis Patients: A Pooled Analysis of 2 Phase III Clinical Trials [13J]
Taylor H, Soliman A, Palac H, Surrey E. Impact of Elagolix on Quality of Life Among Endometriosis Patients: A Pooled Analysis of 2 Phase III Clinical Trials [13J]. Obstetrics And Gynecology 2019, 133: 110-110. DOI: 10.1097/01.aog.0000558829.95268.69.Peer-Reviewed Original ResearchSevere painMonth 3Scale scoreGonadotrophin-releasing hormone antagonistSevere endometriosis-associated painPhase III clinical trialsEndometriosis Health ProfileEndometriosis-associated painPhase III randomizedPlacebo-controlled trialEndometriosis-associated symptomsHealth-related qualityDose-dependent fashionQuality of lifePremenopausal womenHRQL questionnairesMonth 6EHP-30Endometriosis patientsPooled analysisClinical trialsMonths 1Health profileBaseline scoresElagolixEffects of bazedoxifene/conjugated estrogens on reproductive endocrinology and reproductive tract ultrasonographic appearance in premenopausal women: a preliminary study
Flores VA, Leone C, Taylor HS, Stachenfeld NS. Effects of bazedoxifene/conjugated estrogens on reproductive endocrinology and reproductive tract ultrasonographic appearance in premenopausal women: a preliminary study. Gynecological Endocrinology 2019, 35: 390-394. PMID: 30668182, DOI: 10.1080/09513590.2018.1559288.Peer-Reviewed Original ResearchConceptsBZA/CEPremenopausal womenConjugated estrogensReproductive hormonesUltrasonographic appearanceBazedoxifene/conjugated estrogensAbnormal ovarian folliculogenesisReproductive hormone changesCase series studyUnited States FoodEstrogen-receptor complexEndometrial alterationsDaily administrationSerum assessmentLH surgeMenopausal womenMenopausal symptomsMenstrual cycleClinical trialsEndocrinologic functionsOvarian morphologyHormone levelsPosttreatment valuesMurine modelOvarian folliculogenesis
2017
Current and Emerging Medical Treatments for Uterine Fibroids
Chwalisz K, Taylor H. Current and Emerging Medical Treatments for Uterine Fibroids. Seminars In Reproductive Medicine 2017, 35: 510-522. PMID: 29100239, DOI: 10.1055/s-0037-1606302.Peer-Reviewed Original ResearchMeSH KeywordsCombined Modality TherapyCost of IllnessDrug ApprovalDrugs, InvestigationalEvidence-Based MedicineFemaleGonadotropin-Releasing HormoneHormone AntagonistsHumansLeiomyomaLeiomyomatosisMenorrhagiaQuality of LifeReceptors, ProgesteroneUnited StatesUnited States Food and Drug AdministrationUterine NeoplasmsConceptsUterine fibroidsMedical therapyMedical treatmentOral gonadotropin-releasing hormone antagonistLong-term medical therapyGonadotropin-releasing hormone antagonistCommon uterine neoplasmPressure-related symptomsHeavy menstrual bleedingProgesterone receptor modulatorsRandomized clinical trialsSymptomatic uterine fibroidsUnited States FoodMenstrual bleedingUterine neoplasmsSymptom managementSurgical interventionHormone antagonistClinical trialsReceptor modulatorsMedical optionsEffective treatmentClinical developmentFibroidsDrug AdministrationKnowledge of clinical trials regarding hormone therapy and likelihood of prescribing hormone therapy
Taylor HS, Kagan R, Altomare CJ, Cort S, Bushmakin AG, Abraham L. Knowledge of clinical trials regarding hormone therapy and likelihood of prescribing hormone therapy. Menopause The Journal Of The North American Menopause Society 2017, 24: 27-34. PMID: 27575548, DOI: 10.1097/gme.0000000000000711.Peer-Reviewed Original ResearchConceptsPrimary care physiciansObstetrician/gynecologistsHormone therapyCare physiciansMenopausal symptomsPrescribing practicesHT trialsHormone therapy trialsHT knowledgeTreatment optionsClinical trialsInternet-based surveyMale physiciansTrial knowledgePrimary analysisTherapy trialsModerate positive correlationSecondary analysisFemale physiciansPhysiciansPractice typeTrialsGynecologistsTherapySymptoms
2016
Consensus on Recording Deep Endometriosis Surgery: the CORDES statement†
Vanhie A, Meuleman C, Tomassetti C, Timmerman D, D'Hoore A, Wolthuis A, Van Cleynenbreugel B, Dancet E, Van den Broeck U, Tsaltas J, Renner SP, Ebert AD, Carmona F, Abbott J, Stepniewska A, Taylor H, Saridogan E, Mueller M, Keckstein J, Pluchino N, Janik G, Zupi E, Minelli L, Cooper M, Dunselman G, Koh C, Abrao MS, Chapron C, D'Hooghe T. Consensus on Recording Deep Endometriosis Surgery: the CORDES statement†. Human Reproduction 2016, 31: 1219-1223. PMID: 27094477, DOI: 10.1093/humrep/dew067.Peer-Reviewed Original ResearchConceptsDeep endometriosisSurgical treatmentOutcome trialsInternational expert consensusEndometriosis surgeryStandardized reportingClinical trialsPersonal feesExpert consensusSystematic reviewDeep endometriosis surgerySymptomatic deep endometriosisHigh-quality RCTsPost-operative dataPARTICIPANTS/MATERIALSDifferent surgical techniquesROLE OF CHANCEInternational consensusSystematic literature reviewBiobanking Harmonisation ProjectInternational expertsClinical outcomesPain assessmentSurgical managementPatient population
2015
Predictors of participant retention in infertility treatment trials
Kuang H, Jin S, Thomas T, Engmann L, Hansen KR, Coutifaris C, Casson P, Christman G, Alvero R, Santoro N, Eisenberg E, Diamond MP, Legro RS, Zhang H, Network R, Bartlebaugh C, Dodson W, Estes S, Gnatuk C, Ladda R, Ober J, Easton C, Hernandez A, Leija M, Pierce D, Bryzski R, Awonuga A, Cedo L, Cline A, Collins K, Krawetz S, Puscheck E, Singh M, Yoscovits M, Barnhart K, Lecks K, Martino L, Marunich R, Snyder P, Schlaff W, Comfort A, Crow M, Hohmann A, Mallette S, Ringbloom M, Tang J, Mason S, DiMaria N, Rhea M, Turner K, Haisenleder D, Trussell J, DelBasso D, Li Y, Makuch R, Patrizio P, Sakai L, Scahill L, Taylor H, Thomas T, Tsang S, Zhang M, Lamar C, DePaolo L, Guzick D, Herring A, Redmond J, Thomas M, Turek P, Wactawski-Wende J, Rebar R, Cato P, Dukic V, Lewis V, Schlegel P, Witter F. Predictors of participant retention in infertility treatment trials. Fertility And Sterility 2015, 104: 1236-1243.e2. PMID: 26354094, PMCID: PMC4630082, DOI: 10.1016/j.fertnstert.2015.08.001.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdolescentAdultChi-Square DistributionDrug Therapy, CombinationFemaleFertilityFertility Agents, FemaleHumansInfertility, FemaleLogistic ModelsMaleMultivariate AnalysisOdds RatioPatient DropoutsPatient SelectionPolycystic Ovary SyndromePregnancyRandomized Controlled Trials as TopicRisk FactorsTreatment OutcomeYoung AdultConceptsPolycystic ovary syndromeBody mass indexClomiphene citrateClinical trialsHistory of smokingInsurance coverageCombination of metforminMultivariable logistic modelAcademic medical centerRetention of subjectsConduct of RCTsBetter insurance coverageUnexplained infertilityOvary syndromeNormal weightMass indexOriginal RCTTreatment trialsMedical CenterMAIN OUTCOMEWhite raceIntervention studiesRCTsSecondary analysisParticipant retention
2014
Uterine Fibroids: Clinical Manifestations and Contemporary Management
Doherty L, Mutlu L, Sinclair D, Taylor H. Uterine Fibroids: Clinical Manifestations and Contemporary Management. Reproductive Sciences 2014, 21: 1067-1092. PMID: 24819877, DOI: 10.1177/1933719114533728.Peer-Reviewed Original ResearchConceptsMedical therapyUterine fibroidsGrowth factorAbnormal uterine bleedingHeavy menstrual bleedingInterventional radiological proceduresEndometrial effectsUterine bleedingMenstrual bleedingMedical managementSurgical managementCommon lesionsCurrent armamentariumFibroid treatmentClinical trialsEffective treatmentFibroidsRadiological proceduresDrug AdministrationFibroid cellsNovel therapeuticsAbnormal regulationTherapyFibroid biologyMolecular changesThe KEEPS-Cognitive and Affective Study: Baseline Associations between Vascular Risk Factors and Cognition
Wharton W, Gleason CE, Dowling NM, Carlsson CM, Brinton EA, Santoro MN, Neal-Perry G, Taylor H, Naftolin F, Lobo RA, Merriam G, Manson JE, Cedars MI, Miller VM, Black DM, Budoff M, Hodis HN, Harman SM, Asthana S. The KEEPS-Cognitive and Affective Study: Baseline Associations between Vascular Risk Factors and Cognition. Journal Of Alzheimer’s Disease 2014, 40: 331-341. PMID: 24430001, PMCID: PMC4367860, DOI: 10.3233/jad-130245.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultAttentionBlood GlucoseBlood PressureCholesterol, HDLCholesterol, LDLCognition DisordersDouble-Blind MethodEstradiolEstrogensFemaleHormonesHumansLongitudinal StudiesMiddle AgedMood DisordersNeuropsychological TestsPsychiatric Status Rating ScalesRisk FactorsConceptsVascular risk factorsSystolic blood pressureBlood pressureRisk factorsAlzheimer's diseaseCognitive dysfunctionMidlife vascular risk factorsOral conjugated equine estrogenHigher systolic blood pressureConjugated equine estrogensLower blood pressureSerum estradiol levelsHigh blood pressurePostmenopausal womenVascular riskBP levelsEquine estrogensEstradiol levelsMenopausal womenParallel groupClinical trialsHormone levelsCognitive domainsBaseline associationsCognitive decline
2012
Genetic polymorphisms associated with carotid artery intima-media thickness and coronary artery calcification in women of the Kronos Early Estrogen Prevention Study
Miller VM, Petterson TM, Jeavons EN, Lnu AS, Rider DN, Heit JA, Cunningham JM, Huggins GS, Hodis HN, Budoff MJ, Santoro N, Hopkins PN, Lobo RA, Manson JE, Naftolin F, Taylor HS, Harman SM, de Andrade M. Genetic polymorphisms associated with carotid artery intima-media thickness and coronary artery calcification in women of the Kronos Early Estrogen Prevention Study. Physiological Genomics 2012, 45: 79-88. PMID: 23188791, PMCID: PMC3546410, DOI: 10.1152/physiolgenomics.00114.2012.Peer-Reviewed Original ResearchConceptsCarotid artery intima-media thicknessKronos Early Estrogen Prevention StudyMenopausal hormone treatmentCoronary artery calcificationArtery intima-media thicknessIntima-media thicknessCardiovascular diseaseArtery calcificationSingle nucleotide polymorphismsPrevention StudyProgression of CVDSubclinical cardiovascular diseaseInnate immunity pathwaysMultiple testingAgatston unitsCAC scoreWaist circumferenceThrombosis riskPulse pressureClinical trialsHormone treatmentLogistic regressionImmunity pathwaysGenetic polymorphismsCandidate gene variationsThe Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: Rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome
Legro RS, Kunselman AR, Brzyski RG, Casson PR, Diamond MP, Schlaff WD, Christman GM, Coutifaris C, Taylor HS, Eisenberg E, Santoro N, Zhang H, Network F. The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: Rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome. Contemporary Clinical Trials 2012, 33: 470-481. PMID: 22265923, PMCID: PMC3312939, DOI: 10.1016/j.cct.2011.12.005.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsChi-Square DistributionClomipheneDouble-Blind MethodFemaleFertility Agents, FemaleHealth Status IndicatorsHirsutismHumansHyperandrogenismInfertility, FemaleLetrozoleMiddle AgedNitrilesOvulation InductionPolycystic Ovary SyndromePregnancyQuality of LifeResearch DesignTriazolesWomen's HealthYoung AdultConceptsPolycystic ovary syndromeClomiphene citrateOvary syndromeInfertile womenTreatment armsDouble-blind clinical trialSelective estrogen receptor modulatorsMajor infertility factorOral clomiphene citrateMultiple pregnancy rateFirst-line treatmentLive birth rateEstrogen receptor modulatorsDifferent treatment armsTreatment of infertilityPoor ovulatory responseEndometrial effectsII trialII studyLine treatmentInfertility factorsProgestin withdrawalAromatase inhibitorsClinical trialsFemale infertility
2010
Effects of bazedoxifene/conjugated estrogens on metabolic parameters: a randomized, placebo-controlled clinical trial in postmenopausal women
Taylor H, Mirkin S, Chines A. Effects of bazedoxifene/conjugated estrogens on metabolic parameters: a randomized, placebo-controlled clinical trial in postmenopausal women. Fertility And Sterility 2010, 94: s44. DOI: 10.1016/j.fertnstert.2010.07.170.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply